title: Palliation and survival after repeated (188)Re-HEDP therapy of hormone-refractory bone metastases of prostate cancer: a retrospective analysis.
abstract: This retrospective study compared the effects of single and multiple administrations of (186)Re-hydroxyethylidenediphosphonate ((186)Re-HEDP) on palliation and survival of prostate cancer patients presenting with more than 5 skeletal metastases.
  
  
  METHODS
  A total of 60 patients were divided into 3 groups. Group A (n = 19) consisted of patients who had received a single injection; group B (n = 19), patients who had 2 injections; and group C (n = 22), patients who had 3 or more successive injections. The (188)Re-HEDP was prepared using non-carrier-added (188)Re obtained from an in-house (188)W/(188)Re generator after dilution with carrier perrhenate. Patients' data available from the referring physicians-including prostate-specific antigen levels-were entered into a Windows-based matrix and analyzed using a statistical program. The Gleason scores were similar for all 3 groups.
  
  
  RESULTS
  Mean survival from the start of treatment was 4.50 ± 0.81 mo (95% confidence interval [CI], 2.92-6.08) for group A, 9.98 ± 2.21 mo (95% CI, 5.65-14.31) for group B, and 15.66 ± 3.23 (95% CI, 9.33-22.0) for group C. Although the 3 groups did not differ in Gleason score, the number of lost life-years was significantly lower in group C than in groups A and B. Pain palliation was achieved in 89.5% of group A, 94.7% of group B, and 90.9% of group C.
  
  
  CONCLUSIONS
  Posttreatment overall survival could be improved from 4.50 to 15.66 mo by multiple-injection bone-targeted therapy with (188)Re-HEDP, when compared with a single injection. Significant pain palliation was common and independent of administration frequency.
authors: Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany. hans-juergen.biersack@ukb.uni-bonn.de
authors: Hans-Jürgen
authors: HJ
authors: Biersack
authors: Holger
authors: H
authors: Palmedo
authors: Andrej
authors: A
authors: Andris
authors: Stefan
authors: S
authors: Rogenhofer
authors: Furn F
authors: FF
authors: Knapp
authors: Stefan
authors: S
authors: Guhlke
authors: Samer
authors: S
authors: Ezziddin
authors: Jan
authors: J
authors: Bucerius
authors: Dirk
authors: D
authors: von Mallek
mesh_terms: D000368:Aged; D001859:Bone Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000556:secondary* / Q000628:therapy*; D019008:Drug Resistance, Neoplasm / Q000528:radiation effects*; D012968:Etidronic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006728:Hormones / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009942:Organometallic Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D010166:Palliative Care / Q000379:methods*; D011471:Prostatic Neoplasms / Q000473:pathology*; D012189:Retrospective Studies; D016019:Survival Analysis
chemical_list: D006728:Hormones; D009942:Organometallic Compounds; C101598:rhenium-186 HEDP; D012968:Etidronic Acid